Epidemiology and care management of Paroxysmal Nocturnal Hemoglobinuria (PNH) in a real-world setting in France: Description from the French National Hospitalization Database
PLOS One · 16.04.2026 · 21 (4) · e0339715
DOI: 10.1371/journal.pone.0339715 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 16.04.2026. Verfasst von Régis Peffault de Latour und 7 weiteren Autor:innen. Beteiligte Einrichtung: Saint-Louis Hospital, APHP, Paris, France. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Roche France SAS.
Abstract (Originalsprache)
Introduction
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired stem-cell disease causing anemia, aplasia and thromboses, affecting ~1/80,000 patients in France. Treatment mainly involves C5 inhibitors (C5i) and iterative red-blood-cell transfusions. Recent real-world French data on PNH epidemiology and management are scarce in the era of complement inhibitors. This study described PNH epidemiology, patients’ characteristics, and C5i use.
Methods
This was a non-interventional claims study using secondary data from the French national hospital database. Patients with a hospital diagnosis of PNH (ICD-10 code D59.5) over 2018–2022 were selected, after exclusion of those with other C5i-treated diseases. A subgroup of C5i initiators was followed from initiation to last hospitalization, to describe C5i treatment patterns.
Results
The study included 897 patients: 496 (55.3%) receiving a C5i and 218 (24.3%) initiating treatment over 2018–2022. In 2022, 725 PNH patients were identified (prevalence ~1/94,000). Mean (SD) age was 52.1 (21.1) and 45.7 (19.4) years overall and among C5i initiators, respectively. C5i initiators had 20.9 (6.9) dispensations annually. Most patients initiated with eculizumab (n = 196, 89.9%), and almost half of them (n = 80, 40.8%) switched to ravulizumab.
Conclusion
PNH prevalence was ~ 1/94,000. Most patients initiated eculizumab, with 40.8% switching to ravulizumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Saint-Louis Hospital, APHP, Paris, France.
- Roche S.A.S., Boulogne-Billancourt, France.
- Stève consultants, a Cytel company, Oullins-Pierre-Bénite, France.
ORCID-Profile: David Pau, Stève Bénard, Louis Chillotti
Förderung
- Roche France SAS
Zitieren
APA
Peffault de Latour, R., Pibre, S., Vercruyssen, J., Desjuzeur-Bellais, M. L., Pau, D., Bénard, S., Chillotti, L., & Grandfils, N. (2026). Epidemiology and care management of Paroxysmal Nocturnal Hemoglobinuria (PNH) in a real-world setting in France: Description from the French National Hospitalization Database. PLOS One, 21(4), e0339715. https://doi.org/10.1371/journal.pone.0339715
Vancouver
Peffault de Latour R, Pibre S, Vercruyssen J, Desjuzeur-Bellais ML, Pau D, Bénard S, et al. Epidemiology and care management of Paroxysmal Nocturnal Hemoglobinuria (PNH) in a real-world setting in France: Description from the French National Hospitalization Database. PLOS One. 2026;21(4):e0339715. doi:10.1371/journal.pone.0339715
BibTeX
@article{PeffaultdeLatour2026,
author = {Peffault de Latour, Régis and Pibre, Sophie and Vercruyssen, Julien and Desjuzeur-Bellais, Marie Laetitia and Pau, David and Bénard, Stève and Chillotti, Louis and Grandfils, Nathalie},
title = {Epidemiology and care management of Paroxysmal Nocturnal Hemoglobinuria (PNH) in a real-world setting in France: Description from the French National Hospitalization Database},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {4},
pages = {e0339715},
doi = {10.1371/journal.pone.0339715}
}
EUVIMED